JOAQUÍN
DÍAZ MEDIAVILLA
Investigador hasta 2014
Hospital Clinic Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (22)
2012
-
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease
Haematologica, Vol. 97, Núm. 4, pp. 616-621
-
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Blood, Vol. 119, Núm. 3, pp. 687-691
-
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials
American Journal of Pathology, Vol. 181, Núm. 5, pp. 1870-1878
-
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study
Blood, Vol. 120, Núm. 8, pp. 1589-1596
2011
-
Invasive fungal infections in onco-haematology: A spanish perspective
Revista Espanola de Quimioterapia, Vol. 24, Núm. 3, pp. 168-172
-
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
Blood, Vol. 118, Núm. 17, pp. 4547-4553
-
Recomendaciones para el tratamiento de las infecciones f́ngicas invasoras causadas por hongos filamentosos en pacientes hematológicos
Revista Espanola de Quimioterapia, Vol. 24, Núm. 4, pp. 263-270
2010
-
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
Haematologica, Vol. 95, Núm. 11, pp. 1913-1920
-
Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia
Annals of Hematology, Vol. 89, Núm. 11, pp. 1073-1080
-
Utilización de bisfosfonatos en pacientes con mieloma múltiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en Hematología
Medicina Clinica, Vol. 134, Núm. 6, pp. 268-278
2009
2008
-
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
Blood, Vol. 112, Núm. 9, pp. 3591-3593
-
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin
Blood, Vol. 111, Núm. 7, pp. 3395-3402
2007
2005
-
Genetic abnormalities and patterns of antigenic expression in multiple myeloma
Clinical Cancer Research, Vol. 11, Núm. 10, pp. 3661-3667
-
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA
Blood, Vol. 106, Núm. 12, pp. 3755-3759
2003
-
Autologous stem cell transplantation for primary refractory Hodgkin's disease: Results and clinical variables affecting outcome
Annals of Oncology, Vol. 14, Núm. 5, pp. 745-751
2002
2001
-
Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: A study of the PETHEMA group
British Journal of Haematology, Vol. 114, Núm. 1, pp. 99-103
1998
-
Autologous peripheral blood stem cell transplantation for multiple myeloma: A report of 259 cases from the Spanish Registry
Bone Marrow Transplantation, Vol. 21, Núm. 2, pp. 133-140